A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...

This week’s cyber recap covers AI risks, supply-chain attacks, major breaches, DDoS spikes, and critical vulnerabilities security teams must track.

Purdue faculty, staff and students are invited to participate in the Boiler Up, Hammer Data Challenge ahead of Love Data Week on Feb. 9-13. This annual event is part of the Big Ten Academic Alliance ...

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

Organizations have a wealth of unstructured data that most AI models can’t yet read. Preparing and contextualizing this data is essential for moving from AI experiments to measurable results. In ...

Next week is jampacked with potential market movers, including midweek inflation data and a host of other economic indicators. Several Federal Reserve speeches are also on the docket, as well as the ...

Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to ...

Google is ending its dark web report, with scans stopping Jan. 15, 2026. Google says it is shifting to tools with clearer, actionable guidance. Other dark web monitoring tools and scanners are still ...

Google’s dark web reports gave users important info, but not enough “helpful next steps.” Google’s dark web reports gave users important info, but not enough “helpful next steps.” is a news writer ...

Google has let you scan the dark web for personal information revealed in breaches. That service is going away in early 2026. Google stops scanning for new data on January 15, and deletes all old ...

In my last note on Altimmune, Inc. (ALT) shared in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, ...